Eagle Pharmaceuticals, Inc.
EGRXDelisted Nov 26, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000827871
Eagle Pharmaceuticals, Inc. was delisted on Nov 26, 2024; its insiders filed their last Form 4 on Mar 1, 2024; 65 institutions reported holding it in 13F filings for Q3 2024, worth $31.9M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 65
- Q3 2024, −9 vs. previous quarter
- 13F value
- $31.9M
- Reported value at the end of Q3 2024
- Superinvestors holding
- 0
- At the end of Q3 2024
Superinvestors holding EGRX, Q3 2024
No superinvestor reported holding EGRX at the end of Q3 2024.
Latest insider trades
Open-market purchases and sales by Eagle Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 3, 2023 (view filing) | Nov 1-2 | 2 days | Tarriff ScottCEO | SSale | −21.6K | $13.84 | −$299.3K | −3.8%545.4K after | 2 lots10b5-1 |
| Oct 4, 2023 (view filing) | Oct 2-3 | 2 days | Tarriff ScottCEO | SSale | −20.2K | $14.82 | −$300.0K | −3.4%567.1K after | 3 lots10b5-1 |
| May 18, 2023 (view filing) | May 16 | 2 days | Tarriff ScottCEO | SSale | −15.0K | $19.98 | −$299.7K | −2.5%587.3K after | |
| May 15, 2023 (view filing) | May 11-15 | 4 days | Tarriff ScottCEO | SSale | −45.0K | $20.68 | −$930.7K | −2.7%1.59M after | 5 lots |
| Sep 8, 2022 (view filing) | Sep 6 | 2 days | Edlin Richard A.Director | SSale | −6.80K | $30.99 | −$210.7K | −23.1%22.6K after |
Top 10 13F holders, Q3 2024
The largest institutional positions in Eagle Pharmaceuticals, Inc. at the end of Q3 2024; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,356,536 | $8.79M | 0.74% | +394,466+20.1% | Added |
| AIGH Capital Management LLC | 1,211,509 | $4.52M | 2.12% | 00.0% | Unchanged |
| Citigroup Inc | 1,000,389 | $3.73M | 0.00% | −1,166−0.1% | Reduced |
| Vanguard Group Inc | 579,507 | $2.16M | 0.00% | +15,111+2.7% | Added |
| AQR Capital Management LLC | 374,992 | $1.40M | 0.00% | −321,805−46.2% | Reduced |
| BlackRock, Inc. | 268,169 | $1.00M | 0.00% | +268,169 | New |
| Renaissance Technologies LLC | 256,350 | $956.2K | 0.00% | +12,100+5.0% | Added |
| Marshall Wace, LLP | 223,353 | $833.1K | 0.00% | +27,878+14.3% | Added |
| Morgan Stanley | 192,213 | $717.0K | 0.00% | −108,235−36.0% | Reduced |
| Two Sigma Advisers, LP | 185,058 | $690.3K | 0.00% | −39,759−17.7% | Reduced |
Holders of 5% or more of EGRX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Eagle Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 13G/A | 38.08%4.95M shares | 0.00 ppfrom 38.08% | Feb 19, 20252 filings | Aug 14, 2025 | SEC |
| Union Square Park Capital Management, LLC | 13G/A | 11.44%1.49M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Nantahala Capital Partners Limited Partnership | 13G | 6.24%810.6K shares | New | Feb 19, 20251 filing | Feb 19, 2025 | SEC |
| J. Goldman & Co LP | 13G | 5.10%667.1K shares | New | Aug 14, 20251 filing | Aug 14, 2025 | SEC |